Este sitio web utiliza cookies propias para ofrecer un mejor servicio. Si continúa navegando consideramos que acepta su uso. Encontrará más información en nuestra Política de Cookies.
OK | Más informaciónSolicitudes publicadas en los últimos 90 días / Applications published in the last 90 days
Publication No.: US2023167478A1 01/06/2023
Applicant:
UNIV TEXAS [US]
UNIV INDIANA TRUSTEES [US]
Absstract of: US2023167478A1
In a general aspect, microorganisms [e.g., bacteria, etc.) are identified and detected. In some examples, a liquid solvent is supplied through a first channel of a sampling probe to an internal reservoir of the sampling probe; a fixed volume of the liquid solvent in the internal reservoir is held in direct contact with a sample surface for a period of time to form a liquid analyte; gas is supplied to the internal reservoir through a second channel of the sampling probe; the liquid analyte is extracted from the internal reservoir through a third channel of the sampling probe; the liquid analyte is transferred to a mass spectrometer; the mass spectrometer processes the liquid analyte to produce mass spectrometry data; and the mass spectrometry data are analyzed to detect and identify a microorganism [e.g., acteria, fungi, or another type of microorganism) present at the sample surface.
Publication No.: US2023165955A1 01/06/2023
Applicant:
UNIV FLORIDA [US]
Absstract of: US2023165955A1
Disclosed herein are unique adjuvant compositions comprising an attenuated derivative of a self-destructing bacterial pathogen that undergoes lysis in vivo. In exemplary embodiments, the bacterial pathogen is a Salmonella spp. Also disclosed are methods for enhancing an immune response using the adjuvants disclosed herein.
Publication No.: JP2023075356A 30/05/2023
Applicant:
ボードオブトラスティーズオブミシガンステイトユニバーシティ
Absstract of: WO2019045791A1
Provided herein are vaccine composition comprising an antigen conjugated to a capsid, wherein the capsid comprises wild type or native sequence. Provided herein are also vaccine composition comprising an antigen conjugated to a capsid, wherein said capsid comprises at least one mutation, such as a non-natural mutation. Such compositions are useful in the treatment and prevention of pathogenic infections, inflammatory diseases, and neurodegenerative disease, and cancer, among others.
Publication No.: JP2023522475A 30/05/2023
Applicant:
ボードオブリージェンツ,ザユニバーシティオブテキサスシステム
Absstract of: WO2021222182A1
In a general aspect, microorganisms [e.g., bacteria, etc.) are identified and detected. In some examples, a liquid solvent is supplied through a first channel of a sampling probe to an internal reservoir of the sampling probe; a fixed volume of the liquid solvent in the internal reservoir is held in direct contact with a sample surface for a period of time to form a liquid analyte; gas is supplied to the internal reservoir through a second channel of the sampling probe; the liquid analyte is extracted from the internal reservoir through a third channel of the sampling probe; the liquid analyte is transferred to a mass spectrometer; the mass spectrometer processes the liquid analyte to produce mass spectrometry data; and the mass spectrometry data are analyzed to detect and identify a microorganism [e.g., bacteria, fungi, or another type of microorganism) present at the sample surface.
Publication No.: KR20230074410A 30/05/2023
Applicant:
헤파이스토스파마
Absstract of: WO2021180972A1
The invention relates to an enriched population of modified lipopolysaccharide (LPS) molecular species being: - devoid of phosphate group at position C1 of the reducing end of their lipid A domain; and - substituted at position C6' of the non-reducing end of their lipid A domain by a hydrophilic moiety, with the proviso that said hydrophilic moiety is not a hydroxyl group. It also relates to compositions comprising the enriched population of modified LPS; and uses of naturally-occurring LPS molecular species and/or enriched population of modified LPS molecular species for treating and/or preventing cancer, inflammatory diseases or infectious diseases, and for stimulating an immune response or vaccinating a subject.
Publication No.: US2023158133A1 25/05/2023
Applicant:
VAXIMM AG [CH]
Absstract of: US2023158133A1
The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding Wilms' Tumor Protein (WT1), for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one checkpoint inhibitor, particularly selected from at least one antibody against PD-1, PD-L1, CTLA-4, IDO, OX-40, GITR, TIM-3, and LAG-3. The present invention further relates to a pharmaceutical composition comprising an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding WT1 for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one checkpoint inhibitor, particularly selected from at least one antibody against PD-1, PD-L1, CTLA-4, IDO, OX-40, GITR, TIM-3, and LAG-3.
Publication No.: WO2023091873A1 25/05/2023
Applicant:
UNIV ILLINOIS [US]
HERGENROTHER PAUL J [US]
MUNOZ KRISTEN A [US]
Absstract of: WO2023091873A1
Small molecule inhibitors of the localization of lipoprotein CDE (LolCDE) complex that is found in the membrane of bacteria. Searches for suitable candidates for the LolCDE complex led to the discovery of an inhibitor named lolamycin. Lolamycin specifically targets Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Salmonella typhimurium, and is selective over Gram-negative and Gram-positive commensal bacteria, thereby avoiding perturbation of the gut microbiome.
Publication No.: KR20230070521A 23/05/2023
Applicant:
더보드오브트러스티스오브더유니버시티오브아칸소
Absstract of: WO2017192671A1
Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition. Methods of using the vaccine composition to vaccinate subjects are also provided.
Publication No.: WO2023086942A2 19/05/2023
Applicant:
UNIV FLORIDA STATE RES FOUND INC [US]
Absstract of: WO2023086942A2
Disclosed herein are methods and kits for quantifying the presence of a microorganism in a sample. Specifically, disclosed are methods for quantifying a pathogen in a sample, such as a food sample, to determine if the levels of pathogen present in the sample are within an acceptable range.
Publication No.: US2023152320A1 18/05/2023
Applicant:
UNIV MARYLAND [US]
UNIV MARYLAND [US]
Absstract of: US2023152320A1
An apparatus is provided for airborne pathogen detection, which includes a crystal microbalance. The apparatus includes specific capture probes that are affixed to the crystal microbalance and are designed to bind to and capture a specific pathogen, such as a virus particle. This capture causes a change in mass of the crystal microbalance that can be detected. A method is provided for airborne pathogen detection, which includes calibrating a resonant frequency of the crystal microbalance to a mass on the crystal microbalance. The method also includes a step of conjugating the antibody to the crystal microbalance. The method also includes, for each measurement time, measuring a resonant frequency of the crystal microbalance and determining a mass change due to binding of the pathogen to the detector. This mass change is then related to pathogen load in the medium. A notification is output if the viral load exceeds a predetermined threshold.
Publication No.: US2023149524A1 18/05/2023
Applicant:
SERUM INSTITUTE OF INDIA PVT LTD [IN]
Absstract of: US2023149524A1
The present disclosure relates to novel immunogenic monovalent and multivalent polysaccharide-protein conjugate vaccine compositions comprising a polysaccharide selected from Salmonella serovar strains S. typhi; S. paratyphi A; S. typhimurium and S. enteritidis and alternative improved methods of polysaccharide fermentation, polysaccharide purification, polysaccharide-protein conjugation and stable formulation. The present disclosure further relates to methods for inducing an immune response in subjects against Salmonella typhi and non-typhi related diseases and/or for reducing or preventing Salmonella typhi and non-typhi related diseases in subjects using the compositions disclosed herein. The vaccine elicits bactericidal antibodies and is useful for prevention of gastroenteritis, enteric and typhoid fever.
Publication No.: EP4179102A1 17/05/2023
Applicant:
GLYCOM AS [DK]
Absstract of: WO2022013143A1
The invention relates to a genetically modified microorganism for making an oligosaccharide, preferably of 3-8 monosaccharide units, more preferably of 3-5 monosaccharide units, particularly a HMO, which comprises one or more genes encoding a sucrose utilization system, so the microorganism can use sucrose as a carbon and energy source.
Publication No.: KR20230066249A 15/05/2023
Applicant:
전남대학교산학협력단주식회사씨앤큐어
Absstract of: WO2023080703A1
The present invention pertains to a pharmaceutical composition comprising a Salmonella strain and an immune checkpoint inhibitor as active ingredients for prevention or treatment of cancer. The present invention can be advantageously used as a prophylactic or therapeutic composition that is configured to administer a bacterium and an immune checkpoint inhibitor in combination into cancer, especially, a type of resistant cancer difficult to treat with a single anticancer therapy, to remarkably inhibit the size of a tumor, thereby improving the survival rate.
Publication No.: KR20230066000A 12/05/2023
Applicant:
액팀테라퓨틱스인코퍼레이티드
Absstract of: WO2022036159A2
Provided are attenuated immunostimulatory bacteria with genomes that are modified to, for example, reduce toxicity and improve the anti-tumor activity, such as by increasing accumulation in the tumor microenvironment, particularly in tumor- resident myeloid cells, improving resistance to complement inactivation, reducing immune cell death, promoting adaptive immunity, and enhancing T-cell function. Also provided are immunostimulatory bacteria for use as vaccines, and for delivery of mRNA. The increase in colonization of phagocytic cells improves the delivery of encoded therapeutic products to the tumor microenvironment and to tumors and permits, among other routes, systemic administration of the immunostimulatory bacteria. The increase in colonization of phagocytic cells also provides for use of immunostimulatory bacteria for direct tissue administration for use as vaccines.
Publication No.: US2023146032A1 11/05/2023
Applicant:
ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND [US]
Absstract of: US2023146032A1
Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be used as adjuvants in compositions and methods to potentiate the immune response to immunogens.
Publication No.: JP2023519562A 11/05/2023
Applicant:
エンエーセーオンコイミュニティアクスイェセルスカプ
Absstract of: WO2021198376A1
The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain comprising a DNA molecule comprising a eukaryotic expression cassette encoding at least a COVID-19 coronavirus (SARS-CoV-2) spike (S) protein or a portion thereof. In particular, the present invention relates to the DNA vaccine for use in the prevention and/ or the treatment of coronavirus disease 2019 (COVID-19) or a SARS-CoV-2 infection.
Publication No.: WO2023080703A1 11/05/2023
Applicant:
UNIV NAT CHONNAM IND FOUND [KR]
CHCURE BIOTECH INC [KR]
Absstract of: WO2023080703A1
The present invention pertains to a pharmaceutical composition comprising a Salmonella strain and an immune checkpoint inhibitor as active ingredients for prevention or treatment of cancer. The present invention can be advantageously used as a prophylactic or therapeutic composition that is configured to administer a bacterium and an immune checkpoint inhibitor in combination into cancer, especially, a type of resistant cancer difficult to treat with a single anticancer therapy, to remarkably inhibit the size of a tumor, thereby improving the survival rate.
Publication No.: US2023141226A1 11/05/2023
Applicant:
BOEHRINGER INGELHEIM VETMEDICA GMBH [DE]
Absstract of: US2023141226A1
An immunogenic gel compositions for oral administration and methods of immunizing an animal the methods including administering to the animal a therapeutically effective amount of an immunogenic gel composition comprising an antigen of an animal pathogen and a gel composition for oral administration.
Publication No.: CN116083275A 09/05/2023
Applicant:
广东省科学院微生物研究所(广东省微生物分析检测中心)
Absstract of: CN116083275A
本发明公开了一种印第安纳沙门菌及其应用,属于微生物技术领域。本发明的沙门菌为印第安纳沙门菌(Salmonella enterica subsp.enterica serovar Indiana)Sal29‑51,已于2022年7月15日保藏于广东省微生物菌种保藏中心(GDMCC),保藏地址:中国广州市先烈中路100号大院59号楼5楼,保藏号:GDMCC No:62623。本发明的印第安纳沙门菌Sal29‑51携带多种耐药基因,对多种传统药物表现出耐药性,对目前临床治疗沙门菌感染的一线药物也表现出高水平耐药,对多粘菌素B不敏感,可作为筛选功能微生物/新型抗菌药物的模型材料,具有良好的应用前景。
Publication No.: US2023138583A1 04/05/2023
Applicant:
OHIO STATE INNOVATION FOUNDATION [US]
UNIV NORTH CAROLINA STATE [US]
Absstract of: US2023138583A1
In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Publication No.: US2023137821A1 04/05/2023
Applicant:
GLAXOSMITHKLINE BIOLOGICALS SA [BE]
Absstract of: US2023137821A1
The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.
Publication No.: US2023136602A1 04/05/2023
Applicant:
UNIV OKLAHOMA STATE [US]
UNIV KANSAS [US]
Absstract of: US2023136602A1
Antigenic molecules and compositions described herein protect against infection by typhoidal and non-typhoidal Salmonella serovars. Methods of immunization comprise the use of the antigenic molecules.
Publication No.: US2023140113A1 04/05/2023
Applicant:
LA PIEDRA BIOTECNOLOGIA SPA [CL]
Absstract of: US2023140113A1
The present invention discloses a highly efficient method for detecting opioids, opiates, cannabinoids, or benzodiazepines present in a sample, comprising the steps of adding to said sample an enzyme with β-glucuronidase activity originated from genus Brachyspira or any mutant derived thereof; incubating the sample with the enzyme; and detecting said opioids, opiates, cannabinoids, or benzodiazepines by means of a suitable technique.
Publication No.: WO2023073640A1 04/05/2023
Applicant:
BOEHRINGER INGELHEIM VETMEDICA GMBH [DE]
Absstract of: WO2023073640A1
An immunogenic gel compositions for oral administration and methods of immunizing an animal the methods including administering to the animal a therapeutically effective amount of an immunogenic gel composition comprising an antigen of an animal pathogen and a gel composition for oral administration.
Nº publicación: US2023137174A1 04/05/2023
Applicant:
NEC ONCOIMMUNITY AS [NO]
Absstract of: US2023137174A1
The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain comprising a DNA molecule comprising a eukaryotic expression cassette encoding at least a COVID-19 coronavirus (SARS-CoV-2) spike (S) protein or a portion thereof. In particular, the present invention relates to the DNA vaccine for use in the prevention and/or the treatment of coronavirus disease 2019 (COVID-19) or a SARS-CoV-2 infection.